Abstract
The desensitization process of beta-adrenergic system was assessed by in vivo administration to 7-week old rats of a mixed beta-agonist, metaproterenol (3,5-dehydroxyphenyl-N-isopropyl-amine-beta-ethanol sulphate; T1/2=6 hours), (2 mg/kg/d) in treatments of 12 hours, 2 days and 10 days. The in vitro lipolytic effect of selective beta-adrenergic agonists, dobutamine, salbutamol and BRL 37344, as well as plasma free fatty acid concentrations were measured in treated and control animals given vehicle. Different times of exposure to a beta-agonist induced a loss of responsiveness on lipolytic response mediated by beta1 and beta2-adrenoceptors, as demonstrated by decreased affinity and intrinsic activity (maximal effect) of dobutamine and salbutamol. In contrast, no changes were found in beta3 mediated lipolysis. These observations suggest that beta1, beta2 and beta3-adrenoceptors follow different regulatory patterns. Lack of beta3-adrenoceptor desensitization may have important physiological and therapeutic consequences in the treatment of diseases such as obesity and heart failure.
References
Sep 1, 1992·Journal of Cardiovascular Pharmacology·O E BroddeM C Michel
Jan 1, 1992·The American Journal of Clinical Nutrition·P Arner
May 14, 1992·European Journal of Pharmacology·M L Herepath, K J Broadley
Sep 15, 1992·The Biochemical Journal·J P RevelliJ P Giacobino
Aug 1, 1991·The American Review of Respiratory Disease·H S NelsonR J Martin
Jul 9, 1991·European Journal of Pharmacology·D LanginM Lafontan
Nov 1, 1990·Neuron·R L Huganir, P Greengard
Nov 1, 1990·Journal of Cardiovascular Pharmacology·G PeláO Visioli
May 1, 1990·Trends in Pharmacological Sciences·R J LefkowitzM G Caron
Nov 1, 1986·Journal of Cardiovascular Pharmacology·O E BroddeH R Zerkowski
Sep 8, 1989·Science·L J EmorineA D Strosberg
May 1, 1989·Journal of Molecular and Cellular Cardiology·C R JonesR J Summers
Dec 1, 1989·British Journal of Pharmacology·C Hollenga, J Zaagsma
Sep 1, 1986·Circulation Research·M R BristowS Jamieson
Mar 1, 1982·Metabolism: Clinical and Experimental·T W BurnsD B Bylund
Apr 1, 1984·Endocrinology·G TsujimotoB B Hoffman
Jul 15, 1994·European Journal of Pharmacology·M G Murphy, M Horackova
Jun 1, 1994·The American Journal of Physiology·Y HuW P Schilling
Jan 1, 1994·Life Sciences·T YoshidaM Kondo
Jan 1, 1993·Life Sciences·M SanoI Yamamoto
Apr 15, 1993·Experientia·M Rguez-MariscalJ A Martínez
Nov 3, 2007·Cancer Research·Zhong GuanQuentin Liu
Citations
Apr 2, 2003·Regulatory Peptides·Debbie L HayDavid M Smith
Nov 24, 2004·Clinical and Experimental Hypertension : CHE·Guo HuangXiping Xu
Oct 14, 2005·Obesity Research·Mary Anne Della-FeraClifton A Baile
Oct 26, 2018·American Journal of Respiratory Cell and Molecular Biology·Oleg S MatusovskyAnne-Marie Lauzon
Mar 6, 2010·American Journal of Respiratory Cell and Molecular Biology·Florian BossardChantal Gauthier
Dec 6, 2003·Eating and Weight Disorders : EWD·B BerraondoJ A Martinez
Dec 22, 2000·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·F Marion-LatardV Stich
Nov 27, 2020·BMC Pharmacology & Toxicology·Günther KrumplJuri Hodisch
Feb 24, 1998·Life Sciences·P P VicarioM A Cascieri